Physician profile
Michael Musho
NPI 1548255912
$1,256.88
in general payments reported to CMS, 2019-2025
15 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $850 · 2020: $70.65 · 2023: $142 · 2024: $195.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $337.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $336.71 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $459.68 | 2019-2024 | |
| Daiichi Sankyo INC. | $113.55 | 2019 | |
| Amgen INC. | $111.25 | 2019-2024 | Repatha, Otezla |
| Astrazeneca Pharmaceuticals LP | $95.06 | 2019-2024 | Airsupra, Farxiga |
| Astellas Pharma US INC | $92.95 | 2019 | |
| Pfizer INC. | $79.95 | 2019-2024 | |
| Lilly USA, LLC | $75.13 | 2019-2023 | Trulicity, Mounjaro |
| Merck Sharp & Dohme LLC | $51.41 | 2019 | |
| Abbvie INC. | $50.22 | 2023-2024 | |
| Janssen Biotech, INC. | $41.68 | 2019 | |
| Allergan, INC. | $19.88 | 2020 | |
| Glaxosmithkline, LLC. | $19.43 | 2024 | Trelegy Ellipta |
| Novartis Pharmaceuticals Corporation | $18.60 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $15.40 | 2019 | |
| Sanofi Pasteur INC. | $12.69 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Musho listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.